| (AbbVie) M24-108 | A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT05650632 |
| (AstraZeneca) D7230C00001 | A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT06106945 |
| (AstraZeneca) D7401C00001 / Soundtrack F1 | A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma | Dr Gwynivere Davies | Open to recruitment | NCT06549595 |
| (CCTG) IND.244 | A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma | Dr Graeme Fraser | Open to recruitment | NCT05998642 |
| (CCTG) MY.13 | A PHASE III NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL OF FIXED DURATION VERSUS CONTINUOUS DARATUMUMAB AMONG TRANSPLANT INELIGIBLE OLDER ADULTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA | Dr Hira Mian | Open to recruitment | NCT06182774 |
| (CCTG) SC.26 / EASE | Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia | Dr Alejandro Garcia-Horton | Open to recruitment | NCT04224974 |
| (Incyte) INCA 34176-357 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Dr Alejandro Garcia-Horton | Open to recruitment | NCT06585774 |
| (Servier) DIM-95031-006 / ALIDHE | A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy | Dr Tobias Berg | Open to recruitment | NCT05907057 |
| (SWOG) MYELOMATCH / CCTG ALC.7 | MYELOMATCH, MASTER SCREENING AND REASSESSMENT PROTOCOL (MSRP) FOR TIER ADVANCEMENT IN THE NCI MYELOMATCH CLINICAL TRIALS (NCT # NCT05564390) | Dr Alejandro Garcia-Horton | Suspended/On hold | NCT05564390 |
| OCOG-2023-EMBRACE | A Study of Elranatamab Management with Outpatient and IntermittentDosing in Relapsed/Refractory Multiple Myeloma: EMBRACE Trial | Dr Hira Mian | Open to recruitment | NCT06421675 |
| (CCTG) AL.6 / MM1YA-CTG01 | A measurable residual disease (MRD) focused, phase II study of Venetoclax plus chemotherapy for newly diagnosed younger patients with intermediate risk acute myeloid leukemia: A TIER 1 MYELOMATCH SUBSTUDY | Dr Alejandro Garcia-Horton | Suspended/On hold | NCT05554393 |
| (Janssen) 75276617AML3001 / cAMelot-2 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy | Dr Alejandro Garcia-Horton | Suspended/On hold | NCT06852222 |
| (CCTG) HD.12 / RADAR | A Randomized Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Previously Untreated Stage IA/IIA Hodgkin Lymphoma (RADAR) | Dr Joanne Britto | Open to recruitment | NCT04685616 |
Find a Trial
Contact Us